CTRI/2017/12/011035尚未招募3 期
Single dose intranasal fentanyl for the reduction of pain associated with laser therapy for retinopathy of prematurity : a randomized controlled trial
Surya Childrens Medicare Pvt Ltd Hospital0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Neonates 32-44 weeks postmenstrual age undergoing laser photocoagulation for retinopathy of prematurity
排除标准
- •1.Infant receiving sedation or analgesic medications for any reason.
- •2.Infants on mechanical ventilation.
- •3.Any congenital malformations, or neurological dysfunction.
- •4.Parents refusing consent.
研究者
相似试验
已完成
3 期
se of single dose intranasal fentanyl for the reduction of pain associated with retinopathy of prematurity screening :RCTCTRI/2017/12/011016Surya Hospital110
尚未招募
不适用
Efficacy of intranasal fentanyl for the treatment of moderate to severe pain in adult patients in the emergency departmentACTRN12613000652774Peninsula Health150
已完成
4 期
The efficacy of intranasal fentanyl as an adjunct for pain management in retinopathy of prematurity screeningEfficacy of intranasal fentanyl drops as an adjunct for pain management in retinopathy of prematurity screening.Pain, retinopathy of prematurity, intranasal fentanylTCTR20230109003Bhumibol Adulyadej Hospital49
进行中（未招募）
不适用
Intranasal fentanyl for the treatment of breakthrough pain in cancer patients: a randomised, double-blind, placebo-controlled, cross-over confirmatory trial testing the doses 50, 100 and 200 g fentanyl and placebo in eight break-through pain episodes. - NDBreakthrough PainMedDRA version: 6.1Level: PTClassification code 10058019EUCTR2005-002347-82-ITYCOMED HEADQUARTER175
进行中（未招募）
不适用
Intranasal fentanyl for the treatment of breakthrough pain in cancer patients: A randomised, double-blind, placebo-controlled, cross-over confirmatory trial testing the doses 50, 100 and 200 µg fentanyl and placebo in eight break-through pain episodesBreakthrough PainMedDRA version: 8.1Level: PTClassification code 10064556EUCTR2005-002347-82-DEycomed Danmark ApS175